Drug intelligence / Profile preview

ambroxol + levosalbutamol + guaifenesin

Development stage
Unknown
Lead developer
Alde Medi Impex
Modality
Small Molecules
Administration
Oral
01

Overview

Depex-LS is a fixed-dose combination syrup containing ambroxol, levosalbutamol, and guaifenesin, developed by Alde Medi Impex. It is indicated for the symptomatic relief of productive cough, chest congestion, and bronchospasm associated with respiratory tract disorders such as bronchitis, bronchial asthma, and chronic obstructive pulmonary disease (COPD). Ambroxol acts as a mucolytic agent that thins and loosens thick, viscous mucus, facilitating its clearance from the airways. Levosalbutamol is a selective beta-2 adrenergic receptor agonist that acts as a bronchodilator, relaxing bronchial smooth muscle to improve airflow and ease breathing. Guaifenesin is an expectorant that increases the volume and reduces the viscosity of respiratory tract secretions, making coughs more productive. Together, these three active ingredients work synergistically to clear chest congestion and improve respiratory function.

Brand names
Depex-LS
Other names
Ambroxol + Levosalbutamol + GuaifenesinAmbroxol + Levosalbutamol + Guaifenesin syrupAmbroxol plus levosalbutamol plus guaifenesinAmbroxol plus levosalbutamol plus guaifenesin syrup
02

Targets

GBA1 (Glucosylceramidase)SCN10A (Sodium channel protein type X alpha subunit)ADRB2 (β2)

Beyond the preview

Go deeper on ambroxol + levosalbutamol + guaifenesin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ambroxol + levosalbutamol + guaifenesin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call